Summary
73 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 14 USD is left as net profit.
- It earns 19 USD a year on every 100 USD of invested capital.
- Revenue grew by 15% a year over the last 3 years.
- Analysts expect revenue to grow by 22% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 29.1 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 18% a year over 5 years. Over the last 3 years it grew by 15% a year. For the next fiscal year analysts expect revenue to grow by 22%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 71 USD
- Research and development 2.1 USD
- Sales and administration 6.2 USD
- Taxes and other 6.6 USD
- Net profit 14 USD
Net profit, industry median (Chemicals - Specialty) 6.1 USD
Out of every 100 USD of revenue, 14 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.